Evogene Ltd. (EVGN)
Company Description
Evogene Ltd., together with its subsidiaries, operates as a computational biology company.
It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform.
The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance.
Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms.
The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses.
The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally.
The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer.
Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
| Country | Israel |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 137 |
| CEO | Ofer Haviv CPA |
Contact Details
Address: 13 Gad Feinstein Street, Park Rehovot P.o.b 2100 Rehovot, L3 76121 Israel | |
| Phone | 97289311900 |
| Website | evogene.com |
Stock Details
| Ticker Symbol | EVGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001574565 |
| CUSIP Number | M4119S104 |
| ISIN Number | IL0011050551 |
| SIC Code | 2870 |
Key Executives
| Name | Position |
|---|---|
| Ofer Haviv CPA | Chief Executive Officer and Pres |
| Mark Kapel | Chief Technology Officer |
| Dr. Elran Hillel Haber M.B.A., Ph.D. | Chief Executive Officer of Biomica Ltd |
| Yaron Eldad | Chief Financial Officer |
| Dr. Eyal Emmanuel | Chief Scientific Officer |
| Sassi Masliah | Executive Vice President of Corporate Development |
| Liat Foigel Wejgman | Vice President of Human Resources |
| Dr. Nir Arbel | Chief Product Officer |
| Dotan Borenstein | Chief Business Officer of Lavie Bio Ltd. |
| Eyal Ronen | Executive Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2023 | 6-K | Report of foreign issuer |
| Nov 8, 2023 | 6-K | Report of foreign issuer |
| Sep 21, 2023 | 6-K | Report of foreign issuer |
| Sep 19, 2023 | 6-K | Report of foreign issuer |
| Sep 13, 2023 | 6-K | Report of foreign issuer |
| Aug 23, 2023 | 6-K | Report of foreign issuer |
| Aug 17, 2023 | 6-K | Report of foreign issuer |
| Aug 8, 2023 | 6-K | Report of foreign issuer |
| Jul 18, 2023 | 424B5 | Filing |
| Jul 17, 2023 | 6-K | Report of foreign issuer |